BioSpace News Archive

New Drug Application (NDA) for relugolix monotherapy tablet in advanced prostate cancer accepted for Priority Review by the FDA with target action date of December 20, 2020 NDA for relugolix combination tablet in uterine fibroids submitted in May 2020 Additional USD 200 million low-interest, five-year term loan commitment from Sumitomo Dainippon Pharma and commercial collaboration agreement with Sunovion Pharmaceuticals increases financial flexibility and provides access to well-establis

RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com), developer of patented technologies for spraying self-donated stem cells for the regeneration of skin and other organs and tissues, today announced that the US Food and Drug Administration (FDA) conditionally approved the Company’s Investigational Device Exemption (IDE) application to conduct a clinical trial to evaluate the safety and feasibility of autologous stem cells rendered by its Ce

CEL-SCI Corporation (NYSE American: CVM) today reported financial results for the quarter ended June 30, 2020 and provided an update on clinical developments: CEL-SCI reached the targeted threshold of 298 events (deaths) required to conduct the data evaluation for its global pivotal Phase 3 head and neck cancer study of Multikine* (Leukocyte Interleukin, Inj.) immunotherapy. The study is currently in the database l

Company Plans to File Q2 2020 10-Q on August 13, 2020 Save the Date: Company to host virtual disease awareness event on October 20, 2020 focused on cancer therapy-related diarrhea

Revance Announces Two Peer-Reviewed Publications Reporting Safety and Efficacy Results from the SAKURA 3 Open-Label Safety Study in Dermatologic Surgery - The SAKURA 3 safety and efficacy results are consistent with those observed in SAKURA 1 and SAKURA 2 studies for DaxibotulinumtoxinA for Injection in the treatment of glabellar (frown) lines – NEWARK, Calif.--( BUSINESS WIRE )-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company fo

Effective June 1, 2020, List Biological Laboratories, Inc. has reorganized their management team to better apply the wide-ranging skills of their executives.

Coming this September, Livestream #Act4Impact Fundraiser Hosted by Queen Latifah Will Entertain and Do Good

AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and COVID-19 research, announces that its wholly-owned research and development subsidiary, Sapphire Biotech, Inc.

Research collaboration expanding to address urgent public health challenges including supporting FDA’s goal of rapid understanding of COVID-19

Growing bench of proven leaders in clinical lung intelligence and health technology bolsters both product and commercial advances